Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-228
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
0.040(2.85%) |
Mkt cap ! $242.9M |
Open | High | Low | Value | Volume |
$1.40 | $1.45 | $1.36 | $56.44K | 40.03K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | $1.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.48 | 300 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 1.425 |
1 | 709 | 1.410 |
1 | 206 | 1.405 |
1 | 2360 | 1.400 |
3 | 1870 | 1.390 |
Price($) | Vol. | No. |
---|---|---|
1.480 | 300 | 1 |
1.490 | 3500 | 1 |
1.495 | 7817 | 1 |
1.500 | 13333 | 1 |
1.510 | 2408 | 1 |
Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.43 |
  |
Change
0.040 ( 2.14 %) |
|||
Open | High | Low | Volume | ||
$1.36 | $1.44 | $1.36 | 18648 | ||
Last updated 15.59pm 29/05/2024 ? |
Featured News
RAC (ASX) Chart |